The test, sold by C2N Diagnostics, hasn't received FDA's approval, and only doctors are able to order it, in today's bite-sized hospital and health industry news from California, the District of Columbia, and Missouri.
- California: Delvecchio Finley, CEO of Alameda Health System, resigned from the post last week. Finley had served as CEO of Alameda for more than five years and. In a statement, Alameda's board of trustees thanked Finley for leading the health system amid "the most tumultuous period in health care" (Ellison, Becker's Hospital Review, 11/27).
- District of Columbia: Scott Atlas, a former radiologist and member of the White House coronavirus task force, resigned from his position on the task force on Monday. According to Politico, Atlas often clashed with public health experts on the task force who believed that Atlas was misleading President Trump on the outlook of America's coronavirus epidemic. In his resignation letter, Atlas wrote that he "always relied on the latest science and evidence, without any political consideration or influence" (Diamond, Politico, 11/30; Swan/Chen, Axios, 11/30).
- Missouri: C2N Diagnostics has begun selling its blood test for Alzheimer's disease, which is the first of its kind, in most U.S. states and in Europe. The test measures amyloid particles and different forms of protein in a person's blood, and then combines those results with a formula that's intended to determine whether a person has a low, medium, or high risk of developing Alzheimer's disease. The test hasn't received FDA's approval, and it isn't covered by private health plans or Medicare. Only doctors are able to order the test, which is priced at $1,250. The test is intended for screening individuals ages 60 and older who are experiencing cognitive issues and are under evaluation for Alzheimer's (Marchione, Associated Press, 11/30; Axios, 11/30; Budryk, The Hill, 11/30).